BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24746902)

  • 1. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
    Singh N; Patra S
    Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
    Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
    J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
    Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
    Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
    Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
    J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
    Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
    Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
    Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
    Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrolysis of the non-canonical cyclic nucleotide cUMP by PDE9A: kinetics and binding mode.
    Scharrenbroich J; Kaever V; Dove S; Seifert R; Schneider EH
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):199-208. PubMed ID: 30443663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
    Lee DI; Zhu G; Sasaki T; Cho GS; Hamdani N; Holewinski R; Jo SH; Danner T; Zhang M; Rainer PP; Bedja D; Kirk JA; Ranek MJ; Dostmann WR; Kwon C; Margulies KB; Van Eyk JE; Paulus WJ; Takimoto E; Kass DA
    Nature; 2015 Mar; 519(7544):472-6. PubMed ID: 25799991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction.
    Methawasin M; Strom J; Borkowski T; Hourani Z; Runyan R; Smith JE; Granzier H
    Circ Heart Fail; 2020 May; 13(5):e006609. PubMed ID: 32418479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-4 as a potential drug target.
    Zhang KY; Ibrahim PN; Gillette S; Bollag G
    Expert Opin Ther Targets; 2005 Dec; 9(6):1283-305. PubMed ID: 16300476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
    Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
    J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
    [No Abstract]   [Full Text] [Related]  

  • 13. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
    Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
    Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
    Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
    J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.
    Meng F; Hou J; Shao YX; Wu PY; Huang M; Zhu X; Cai Y; Li Z; Xu J; Liu P; Luo HB; Wan Y; Ke H
    J Med Chem; 2012 Oct; 55(19):8549-58. PubMed ID: 22985069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations.
    Huang J; Hu B; Xu Z; Ye Y; Wang H; Wang S; Liu Z; Wang J
    J Mol Model; 2021 Dec; 28(1):9. PubMed ID: 34907481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
    Wang PX; Li ZM; Cai SD; Li JY; He P; Huang Y; Feng GS; Luo HB; Chen SR; Liu PQ
    Acta Pharmacol Sin; 2017 Sep; 38(9):1257-1268. PubMed ID: 28649129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of phosphodiesterase 9A as a cyclic guanosine monophosphate-specific phosphodiesterase in germinal vesicle oocytes: a proposed role in the resumption of meiosis.
    Hanna CB; Yao S; Wu X; Jensen JT
    Fertil Steril; 2012 Aug; 98(2):487-95.e1. PubMed ID: 22704629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.